Highest-materiality recent filing
CytoSorbents shareholders approve reverse stock split and elect directors at annual meeting
All five director nominees elected: Chan, Bator, Jones, Sobel, Kim (for votes 23.7M-24.9M).
CytoSorbents Q2 2026 presentation omits financials; targets H2 2026 break-even
Targets operating cash-flow break-even in H2 2026 via strategic workforce and cost reduction plan.
CytoSorbents Q2 2026 revenue flat at $9.6M; operating loss improves 27%
Revenue $9.6M (unchanged YoY); gross margin 73% (up from 71% YoY).
CytoSorbents receives Nasdaq non-compliance notice for MVLS below $35M
Received Nasdaq notice on June 29, 2026 for failing MVLS requirement (minimum $35M).
Two pre-submission meetings with FDA scheduled for August 2026.
Q1 rev $8.9M (+2%); net loss $5.1M; DrugSorb-ATR FDA submission delayed to late 2026/early 2027
Revenue $8.9M, +2% YoY; gross margin 69% vs 71% in Q1 2025.
CytoSorbents receives Nasdaq extension to Sept 28, 2026 for minimum bid price compliance
Received 180-day extension until Sept 28, 2026 to regain $1.00 minimum bid price compliance.
Revenue $37.1M (+4% YoY); gross margin 71%. Net loss improved to $8.2M ($0.13/sh) from $20.7M loss.
CytoSorbents Reports Q3 2025 Revenue of $9.5M, Up 10% YoY, and Provides Business Update
Revenue was $9.5 million for Q3 2025, a 10% increase from $8.6 million in Q3 2024, driven by record distributor sales.
CytoSorbents (CTSO) receives Nasdaq deficiency notice for bid price below $1.00
Received Nasdaq notice on Oct 2, 2025, for non-compliance with Minimum Bid Price Requirement.
FDA appeal upheld prior De Novo denial for DrugSorb-ATR, citing need for additional label-indication data; no safety issues found.
FDA upholds DrugSorb-ATR De Novo denial but offers path forward
FDA appeal decision found no safety issues with DrugSorb-ATR but upheld the prior De Novo denial.
CytoSorbents Q2 revenue $9.6M (+9% YoY); net income $1.9M but adjusted loss widens
Revenue $9.6M, up 9% YoY (4% constant currency); Germany sales up 22% YoY and sequentially.
Meta-analysis of 744 septic shock patients: CytoSorb reduced in-hospital mortality (OR 0.64, p=0.036) and halved 28–30 day mortality (OR 0.46, p=0.003).
CytoSorbents: FDA appeal hearing set; Health Canada refuses DrugSorb-ATR license
FDA confirmed appeal hearing under 21 CFR 10.75; supervisory review expected to complete by end of August 2025.
CytoSorbents appeals FDA denial of DrugSorb-ATR De Novo request; decision expected ~60 days
Appeal filed June 18, 2025 under 21 CFR 10.75; FDA denial letter dated April 25, 2025.
All five director nominees (Phillip P. Chan, Edward R. Jones, Michael Bator, Alan D. Sobel, Jiny Kim) were elected with strong support.
CytoSorbents Series B Right Warrants expire worthless; VWAP below $2.00 minimum
5-day VWAP prior to June 10, 2025, was below the $2.00 minimum required price.
CytoSorbents Q1 product rev $8.7M (-3%); FDA denies DrugSorb-ATR De Novo
Product revenue $8.7M, flat constant currency vs Q1 2024 $9.0M; gross margin 71% vs 77%.
CytoSorbents receives FDA denial for DrugSorb-ATR De Novo; plans appeal if unresolved
FDA issued denial letter on April 25, 2025 for DrugSorb-ATR De Novo Request, citing remaining deficiencies.
CytoSorbents appoints Melanie Grossman as VP & Corp Controller; issues inducement options and RSUs
Appointment of Melanie Grossman as VP and Corporate Controller, effective April 14, 2025.
Thomas Shannon appointed VP of Marketing, North America; will lead strategy for DrugSorb-ATR in U.S. and Canada.
CytoSorbents extends Series B Right Warrant expiration to June 10, 2025
Expiration date extended from April 10, 2025 to June 10, 2025.
CytoSorbents restates 2023/2024 financials due to inventory and RSU errors
Overstated inventory from clerical error; understated non-cash RSU expense due to using vesting-date fair value instead of grant-date.
CytoSorbents Q4 product rev $9.2M (+25% YoY); FY rev $35.6M (+15%); expects FDA decision 2025
Q4 product revenue $9.2M (+25% YoY); product gross margin 71%; operating loss improved 61% to $3.7M.
Earnings call rescheduled to March 31, 2025 at 4:30 PM ET; annual audit still in progress.
Q4 product revenue expected $9.0-9.2M (22-25% YoY growth); full-year $35.4-35.6M (~14% growth).
CytoSorbents raises $1.6M from Series A warrant exercises; total rights offering proceeds $7.85M
1,417,208 Series A Right Warrants exercised at $1.13 each for $1.6M gross proceeds upon expiration.
CytoSorbents closes oversubscribed rights offering, raises $6.25M, unlocks $5M restricted cash
Rights offering raised $6.25M gross from all 6.25M Units; oversubscribed 68% with 10.5M Units demanded.
CytoSorbents opens regional sales subsidiary in Dubai, UAE
New subsidiary in Dubai Science Park will serve as a sales hub for the Middle East and Africa.
Q4 2024 product revenue est $9.0M-$9.2M, 22-25% YoY growth vs $7.35M in Q4 2023.
CytoSorbents commences rights offering at $1.00/unit, expiring Jan 10, 2025
Record date Dec 16, 2024; one Subscription Right per share of common stock owned.
CytoSorbents launches rights offering of up to 6.25M units at $1.00 each
Record date Dec 16, 2024; basic rights expire Jan 10, 2025; subscription price $1.00 per unit.
CytoSorbents reports Q3 product revenue $8.6M (+11% YoY); net loss narrows to $2.3M
Product revenue $8.6M (+11% YoY); total revenue $9.4M; net loss $2.3M ($0.04/sh) vs $9.2M loss in Q3 2023.
CytoSorbents submits DrugSorb-ATR FDA De Novo for CABG bleeding; Q3 sales $8.3-8.5M
DrugSorb-ATR De Novo application submitted to FDA on Sept 27, 2024 for reducing perioperative bleeding in CABG patients on ticagrelor.
CytoSorbents authorizes up to $20M ATM equity offering of common stock
Company authorized offer and sale of up to $20M common stock under Open Market Sale Agreement with Jefferies LLC.
CytoSorbents amends royalty agreement with ROKK, redefines gross revenue scope
Royalty rate remains 3% of gross revenues from CytoSorb sales under amended agreement.
CytoSorbents appoints Peter J. Mariani as CFO; Kathleen P. Bloch retires
Peter J. Mariani appointed CFO effective Aug 14, 2024; previously CFO of Axogen (2016-2023).
CytoSorbents Q2 product sales up 10%, operating loss halved; DrugSorb-ATR submission on track
Total revenue $9.9M (+5% YoY); product sales $8.8M (+10%); gross margins improved to 75%.
CytoSorbents regains Nasdaq minimum bid price compliance
Received Nasdaq letter on July 26, 2024 confirming compliance after closing bid price at $1.00+ for 10 consecutive days through July 25.
CytoSorbents secures $20M credit facility with Avenue Capital; $10M available at close
Initial tranche $15M with $10M immediately available; $5M released upon FDA acceptance of DrugSorb-ATR De Novo.
All five director nominees (Phillip Chan, Michael Bator, Edward Jones, Alan Sobel, Jiny Kim) elected with majority of votes cast.
CytoSorbents receives Nasdaq delisting notice for bid price below $1.00
Received Nasdaq notice on May 20, 2024 for non-compliance with Minimum Bid Price Requirement.
CytoSorbents Q1 product sales up 14% to $9.0M; gross margin expands to 76%
Product sales $9.0M, +14% YoY from $7.9M and +22% sequentially from Q4 2023 ($7.3M).
CytoSorbents amends bylaws: adds forum selection clause, updates advance notice provisions
Amended bylaws effective May 2, 2024; removes stockholder list inspection requirement per DGCL update.
CytoSorbents executives take salary reduction; CEO by 35%, others by 15%
CEO Phillip Chan reduces salary by 35% ($123,498) to $359,353 through Dec 31, 2024.
CytoSorbents reports 10% core sales growth; plans DrugSorb-ATR submission in H2 2024
FY2023 total revenue $36.3M (+5% YoY); core CytoSorb sales $31.0M (+10%).
Vasoplegic syndrome rate 20% vs 48% control (p=0.028); odds 6.4× lower in CytoSorb group.
STAR-T trial did not meet primary composite effectiveness endpoint in overall 140-patient population.
CytoSorbents closes $10.3M registered direct offering with insider participation
Closed offering of 7,733,090 shares and warrants for 2,706,561 shares at $1.33/unit, gross $10.3M.
the Company also announced the retirement of Ms. Kathleen P. Bloch, the Company’s then serving Chief Financial Officer, and her transition into a consulting role with the Company.
On August 13, 2024, CytoSorbents Corporation (the “Company”) issued a press release announcing the appointment of Peter J. Mariani as the Company’s new Chief Financial Officer, effective as of August 14, 2024
Ms. Bloch will continue to serve as the Company’s Chief Financial Officer.
On August 28, 2023, the Company and Mr. D’Amico mutually agreed to terminate Mr. D’Amico’s employment with the Company.
Mr. D’Amico will serve as the Company’s Chief Financial Officer, effective as of August 7, 2023.
On April 17, 2023, Al W. Kraus notified the Board of Directors (the “Board”) of CytoSorbents Corporation (the “Company”) of his intent to retire and that he will not stand for reelection as a member of the Board
Ms. Kathleen P. Bloch retired from her role as Chief Financial Officer of CytoSorbents Corporation (the “ Company ”), effective as of March 31, 2023.
Ms. Bloch will serve as a consultant to the Company and as the Company’s Interim Chief Financial Officer.
On September 30, 2022, Ms. Kathleen P. Bloch notified CytoSorbents Corporation (the “Company”) and the Board of Directors (the “Board”) of her decision to retire from her role as Chief Financial Officer of the Company, effective as of March 31, 2023.
On April 1, 2022, the Board of Directors (the "Board") of CytoSorbents Corporation (the "Company") increased the size of the Board from five to six, and upon the recommendation of the Company’s Nominating and Corporate Governance Committee, appointed Ms. Jiny Kim to the Board to fill the resulting vacancy.
Max materiality 0.80 · Median 0.65 · Most common event other_material